"In the past few years, there has been considerable discussion around the idea we are slowly merging with our technology, that we are becoming transhuman, with updated abilities, including enhanced intelligence, strength, and awareness," Sahota writes.The goal of the transhumanist movement, or "Human 2.0," is to transcend biology into technology. Or, as Dr. Carrie Madej explains in the video [below], to meld human biology with technology and artificial intelligence.
Health & Wellness

Breathing slowly and deeply through the nose is associated with a relaxation response, says James Nestor, author of Breath. As the diaphragm lowers, you're allowing more air into your lungs and your body switches to a more relaxed state.
Journalist James Nestor became interested in the respiratory system years ago after his doctor recommended he take a breathing class to help his recurring pneumonia and bronchitis.
While researching the science and culture of breathing for his new book, Breath: The New Science of a Lost Art, Nestor participated in a study in which his nose was completely plugged for 10 days, forcing him to breathe solely through his mouth. It was not a pleasant experience.
"I went from snoring a couple minutes a night to, within three days, I was snoring four hours a night," he says of the forced mouth-breathing. "I developed sleep apnea. My stress levels were off the charts. My nervous system was a mess. ... I felt awful."
Nestor says the researchers he's talked to recommend taking time to "consciously listen to yourself and [to] feel how breath is affecting you." He notes taking "slow and low" breaths through the nose can help relieve stress and reduce blood pressure.
Comment: More on the many benefits of deep breathing:
- MindMatters: Breathe Deep to Reap The Benefits of a Healthy Mind: The Tao of Natural Breathing
- The Science of breathing
- Cleansing of the brain affected by breathing
There have been a number of federal actions around the issue of a COVID vaccine in recent weeks. The Centers for Disease Control and Prevention (CDC) released technical guidelines to states, telling them to be prepared to store, distribute, and administer a COVID vaccine as early as late October or early November. Lawmakers have also introduced a bill aimed at instilling public confidence in an eventual COVID vaccine, but the bill does anything but. These actions underscore the need for transparency and freedom of choice when it comes to the issue of vaccination.
Public health experts say that the CDC guidance is meant to prepare states for the monumental task of vaccinating millions of people, but the timing is ominous. We've been told, almost since the pandemic began, that the earliest a vaccine could be expected was in 18 months; now we're told that a vaccine could be mere weeks away — and right before an election. Dr. Anthony Fauci has even said in interviews that vaccine trials could end prematurely if a certain level of safety and effectiveness is demonstrated.
Presumably to dispel fears of political tampering to get a vaccine approved before the election, a group of lawmakers have introduced a bill that would, in short, ensure that the normal procedures for vaccine approval take place and that the recommendations of the CDC and FDA are made public.
The "normal procedures" for vaccine approval hardly instill confidence that a vaccine will be safe. We need only consult the historical record: to date, the US Vaccine Court, in which it is notoriously difficult to win cases, has paid out more than $4 billion to families who have been injured by vaccines.
Comment: More on the dubious Covid vaccine:
- Company set to manufacture COVID-19 vaccine for US intentionally sold faulty biodefense products
- COVID-19 vaccine candidate from Oxford University and AstraZeneca on hold after 'unexplained illness'
- HealthPartners pauses enrollment in COVID-19 vaccine trial while AstraZeneca investigates reported illness
- Top FDA official says he would resign if agency rubber-stamps an unproven COVID-19 vaccine

A researcher works inside a laboratory of the Gamaleya Scientific Research Institute of Epidemiology and Microbiology where the world's first coronavirus vaccine registered in Russia was developed.
On September 7, an open letter signed by twenty-six analysts, mainly based in Italy, cast doubt on Russia's vaccine, noting the discovery of "potential data inconsistencies" in the published research. The group claimed that the article had significant statistical anomalies. Following the letter, the journal's editorial board asked the developers of the Russian vaccine, dubbed Sputnik V, to reply.
According to Alexey Kuznetsov, an assistant to Russia's Minister of Health, the vaccine's creators have sent "detailed responses to the editor of The Lancet magazine."
Comment: See also:
- The Lancet: Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
- Russia produces first batch of COVID-19 vaccine, 500 million doses available by January
- HealthPartners pauses enrollment in COVID-19 vaccine trial while AstraZeneca investigates reported illness
- Huge blow to Bill Gates - Trump withdraws support from COVAX vaccine alliance
- 'Bad optics'? Why are Moderna executives dumping stock while developing a Coronavirus vaccine?
- Sputnik V, world's first Covid-19 vaccine, launched - Putin's daughter among first to take it - Vaccine will NOT be mandatory in Russia
A drink using artemisia plant extracts was promoted by its leader, President Andry Rajoelina.
There's no evidence so far that this plant - whose compounds do work against malaria - can combat Covid-19, according to the World Health Organization (WHO).
So what do we know about the plant and its properties?
Comment: See also:
- Phytomedicine: Critically ill patients with drug-resistant malaria cured using dried leaves of Artemisia annua plant
- Chinese Botanical Medicine: Wikipedia claims it is fake, we are certain it is real
- The looming medical apocalypse: Could ancient remedies hold the answer to the antibiotics crisis?
- At the epicentre of the coronavirus outbreak, Western medicine meets traditional Chinese remedies
Anticholinergic medications block acetylcholine (i.e., "vagusstoff") and inhibit parasympathetic nerve impulses by binding with this neurotransmitter's receptors. Over 600 medications are known to trigger some degree of anticholinergic activity (Ghossein, Kang, & Lakhkar, 2020).
Anticholinergics are a common class of drugs prescribed by doctors — or purchased over-the-counter (OTC) without a prescription — for the treatment of allergies, asthma, common cold symptoms, COPD, hay fever, hypertension, overactive bladder, Parkinson's disease as well as psychiatric disorders, depression, and a host of other ailments.
What Is Acetylcholine and Why Is It Also Called "Vagusstoff"?
Acetylcholine (ACh) was the first neurotransmitter ever discovered by scientists. In 1921, a German-born psychobiologist and pharmacologist, Otto Loewi (1873-1961), identified a substance secreted by the vagus nerve that slowed heart rate. He named this stuff "vagusstoff," which is German for "vagus nerve substance." (See "How Does 'Vagusstoff' (Vagus Nerve Substance) Calm Us Down?")

In large-scale Phase 3 clinical trials, patients receive either an active vaccine or a placebo.
The company put a hold on its COVID-19 clinical trials worldwide while it investigated an adverse reaction in a trial participant in the United Kingdom.
It's not clear how long the stoppage will last. Sometimes reactions happen during a trial that are purely coincidental, but if they are serious enough, research is put on hold until they can be fully investigated.
AstraZeneca said in a statement late Tuesday that the company is testing a vaccine originally developed at Oxford University.
"We are working to expedite the review of the single event to minimize any potential impact on the trial timeline. This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
Comment: U.S. infectious disease 'expert' Anthony Fauci offers his opinion on the efficacy of rapid-testing of vaccine candidate:
Fauci, Director of the U.S. National Institute of Allergy and Infectious Diseases, said the pause was not uncommon.
"This particular candidate from the AstraZeneca company had a serious adverse event, which means you put the rest of the enrollment of individual volunteers on hold until you can work out precisely what went on. It's really one of the safety valves that you have on clinical trials such as this, so it's unfortunate that it happened. Hopefully, they'll work it out and be able to proceed along with the remainder of the trial but you don't know. They need to investigate it further."
The vaccine, which AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization as probably the world's leading candidate and the most advanced in terms of development. Tuesday's move was seen as dimming prospects for an early rollout.
Dyslexia is a frequent disorder of reading acquisition that affects up to 10% of the population, and is characterized by lifelong difficulties with written material. Although several possible causes have been proposed for dyslexia, the predominant one is a phonological deficit, i.e., a difficulty in processing language sounds. The phonological deficit in dyslexia is associated with changes in rhythmic or repetitive patterns of neural activity, specifically the so-called "low-gamma" (30-Hz) oscillations, in a sound-processing region of the brain called left auditory cortex. But a causal relationship between these oscillations and the ability to process phonemes had not been established in previous studies.
Comment: See also:
- Dyslexia related to brain's plasticity
- Study finds less gray matter in brain not the blame for dyslexia
- Root causes of dyslexia unraveled
- NIH-funded study finds dyslexia not tied to IQ
- Dyslexia: Some Very Smart Accomplished People Cannot Read Well
- Thousands of children wrongly diagnosed with dyslexia
- Pre-school age exercises can prevent dyslexia
- 'Number blindness' more common than dyslexia
- Study: Dyslexia Differs by Language
- Having right timing 'connections' in brain is key to overcoming dyslexia

SYDNEY, AUSTRALIA - AUGUST 19: A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
In a statement issued Tuesday evening, AstraZeneca said its "standard review process triggered a pause to vaccination to allow review of safety data."
AstraZeneca didn't reveal any information about the possible side effect except to call it "a potentially unexplained illness." The news site STAT first reported the pause in testing, saying the possible side effect occurred in the United Kingdom.
Comment: After announcing a possible side effect, they're giving the reader instructions on how to enroll in the trial. Is this what they call 'bad optics'?
See also:
- Four EU nations to fund AstraZeneca's COVID-19 vaccines for Europe
- Huge blow to Bill Gates - Trump withdraws support from COVAX vaccine alliance
- March to fascism: Morrison says Covid vaccine likely to be mandatory in Australia, suggests that those who refuse it will starve
- Bubble indemnity: Big Pharma firms will not be held accountable for side effects of Covid vaccine
- When profits and politics drive science: Rushing a vaccine to market for a vanishing virus
- COVID-19 vaccines: Continuing the long history of medical experimentation on children
- Oxford's COVID-19 vaccine trial has 50% chance of success, says report
Recently Dr. Rancourt has turned his attention to the science behind the Covid fiasco. He speaks to us today about his recent research and what he's been able to dig up looking into the all-cause mortality figures. His conclusions are rather stunning!
He also talks about what the research says about masks (spoiler alert: they don't work), and ties the entire Covid episode to geopolitics and the ongoing gloablist agenda. You don't want to miss this one!
Comment: See also: